Top

Published in:

Open Access 01-03-2015 | Original Research

Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry

Authors: Joanne N. Davis, Clinton Medbery III, Sanjeev Sharma, David Perry, John Pablo, David J. D’Ambrosio, Heidi McKellar, Frank C. Kimsey, Paul N. Chomiak, Anand Mahadevan

Published in: Journal of Radiation Oncology | Issue 1/2015

Abstract

Objectives

Stereotactic body radiotherapy (SBRT) is a definitive local treatment option for patients with stage I non-small cell lung cancer (NSCLC) who are not surgical candidates and patients who refuse surgery. The purpose of this study was to assess the impact of SBRT on T1–T2 NSCLC from a national registry, reflecting practices and outcomes in a real-world setting.

Methods

The RSSearch® Patient Registry was screened for T1–T2N0M0 NSCLC patients treated from May 2004 to May 2013 with SBRT. Descriptive analyses were used for patient, tumor, and treatment characteristics. Overall survival (OS) and local control (LC) were calculated using the Kaplan-Meier method.

Results

In total, 723 patients with 517 T1 and 224 T2 lesions were treated with SBRT. Median follow-up was 12 months (1–87 months) with a median age of 76 years. Median SBRT dose was 54 Gy (range 10–80 Gy) delivered in a median of 3 fractions (range 1–5), and median biological equivalent dose (BED₁₀) was 151.2 Gy (range 20–240 Gy). Median OS was 30 and 26 months for T1 and T2 tumors, respectively (p = 0.019). LC was associated with higher BED₁₀ for T2 tumors, but not in T1 tumors at a median follow-up of 17 months. Seventeen-month LC for T2 tumors treated with BED₁₀ < 105 Gy, BED₁₀ 105-149, and BED₁₀ ≥ 150 Gy was 43, 74, and 95 %, respectively (p = 0.011). Local failure rates for T2 tumors treated with BED₁₀ < 105 Gy, 105–149 Gy, and ≥150 Gy were 32, 21, and 8 % (p = 0.029), respectively. Median OS for patients with T2 tumors treated with BED₁₀ < 105 Gy was 17 vs. 32 months for T2 tumors treated with BED₁₀ 105–149 Gy (p = 0.062).

Conclusion

SBRT for T1–T2 NSCLC is feasible and effective in the community setting. OS was greater for patients with T1 lesions compared to T2 lesions. An improvement in LC was observed in patients with T2 lesions treated with BED₁₀ > 105 Gy.

Smythe WR (2003) Treatment of stage I non-small cell lung carcinoma. Chest 123(1 Suppl):181S–187SCrossRefPubMed

Armstrong JG, Minsky BD (1989) Radiation therapy for medically inoperable stage I and II non-small cell lung cancer. Cancer Treat Rev 16(4):247–255CrossRefPubMed

Qiao X, Tullgren O, Lax I, Sirzen F, Lewensohn R (2003) The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 41(1):1–11CrossRefPubMed

Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R (2009) Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol Off J Am Soc Clin Oncol 27(20):3290–3296. doi:10.1200/JCO.2008.21.5681 CrossRef

Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, Sonke JJ, Bissonnette JP, Wilbert J, Xiao Y, Belderbos J (2012) A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol Off Publ Int Assoc Stud Lung Cancer 7(9):1382–1393. doi:10.1097/JTO.0b013e318260e00d

Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T (2007) Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol Off Publ Int Assoc Stud Lung Cancer 2(7 Suppl 3):S94–S100. doi:10.1097/JTO.0b013e318074de34

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA J Am Med Assoc 303(11):1070–1076. doi:10.1001/jama.2010.261 CrossRef

Haasbeek CJ, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S (2010) Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer 116(2):406–414. doi:10.1002/cncr.24759 CrossRefPubMed

Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA, Swisher SG (2012) Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 7:152. doi:10.1186/1748-717x-7-152 CrossRefPubMedCentralPubMed

10.

Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, Timmerman R (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75(3):677–682. doi:10.1016/j.ijrobp.2008.11.042 CrossRefPubMed

11.

Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S (2008) Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70(3):685–692. doi:10.1016/j.ijrobp.2007.10.053 CrossRefPubMed

12.

Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M (2005) Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 63(5):1427–1431. doi:10.1016/j.ijrobp.2005.05.034 CrossRefPubMed

13.

Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S (2012) Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 13(8):802–809. doi:10.1016/S1470-2045(12)70242-5 CrossRefPubMed

14.

Crabtree TD, Denlinger CE, Meyers BF, El Naqa I, Zoole J, Krupnick AS, Kreisel D, Patterson GA, Bradley JD (2010) Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 140(2):377–386. doi:10.1016/j.jtcvs.2009.12.054 CrossRefPubMed

15.

Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, Wloch J, Ye H, Kestin LL (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(6):928–935. doi:10.1200/JCO.2009.25.0928 CrossRef

16.

Verstegen NE, Oosterhuis JW, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, Mollema R, van Tets WF, Warner A, Joosten JJ, Amir MI, Haasbeek CJ, Smit EF, Slotman BJ, Senan S (2013) Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol Off J Eur Soc Med Oncol ESMO 24(6):1543–1548. doi:10.1093/annonc/mdt026 CrossRef

17.

(NCCN) NCCN (2013) National comprehensive practice guidelines in oncology: non-small cell lung cancer. Natl Compr Netw 2:2014

18.

Davis JN, Medbery Iii C, Sharma S, Danish A, Mahadevan A (2013) The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy. Radiat Oncol 8(1):275. doi:10.1186/1748-717X-8-275 CrossRefPubMedCentralPubMed

19.

Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF, Senan S (2012) Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 83(1):348–353. doi:10.1016/j.ijrobp.2011.06.2003 CrossRefPubMed

20.

Salazar OM, Sandhu TS, Lattin PB, Chang JH, Lee CK, Groshko GA, Lattin CJ (2008) Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers. Int J Radiat Oncol Biol Phys 72(3):707–715. doi:10.1016/j.ijrobp.2008.01.054 CrossRefPubMed

21.

van der Voort van Zyp NC, Prevost JB, Hoogeman MS, Praag J, van der Holt B, Levendag PC, van Klaveren RJ, Pattynama P, Nuyttens JJ (2009) Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol J Eur Soc Ther Radiol Oncol 91(3):296–300. doi:10.1016/j.radonc.2009.02.011 CrossRef

22.

Rosenzweig KE, Fox JL, Yorke E, Amols H, Jackson A, Rusch V, Kris MG, Ling CC, Leibel SA (2005) Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 103(10):2118–2127. doi:10.1002/cncr.21007 CrossRefPubMed

23.

Sibley GS (1998) Radiotherapy for patients with medically inoperable Stage I nonsmall cell lung carcinoma: smaller volumes and higher doses—a review. Cancer 82(3):433–438CrossRefPubMed

24.

Stephans KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Mason D, Murthy S, Rice TW, Mazzone P, Machuzak M, Mekhail T, Videtic GM (2009) A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol Off Publ Int Assoc Stud Lung Cancer 4(8):976–982. doi:10.1097/JTO.0b013e3181adf509

25.

Le QT, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H, Kee ST, Constantinescu D, Whyte RI, Donington J (2006) Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol Off Publ Int Assoc Stud Lung Cancer 1(8):802–809

26.

Nuyttens JJ, van der Voort van Zyp NC, Praag J, Aluwini S, van Klaveren RJ, Verhoef C, Pattynama PM, Hoogeman MS (2012) Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother Oncol J Eur Soc Ther Radiol Oncol 102(3):383–387. doi:10.1016/j.radonc.2011.12.023 CrossRef

27.

Onimaru R, Fujino M, Yamazaki K, Onodera Y, Taguchi H, Katoh N, Hommura F, Oizumi S, Nishimura M, Shirato H (2008) Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 70(2):374–381. doi:10.1016/j.ijrobp.2007.06.043 CrossRefPubMed

28.

Jeppesen SS, Schytte T, Jensen HR, Brink C, Hansen O (2013) Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates. Acta Oncol 52(7):1552–1558. doi:10.3109/0284186X.2013.813635 CrossRefPubMed

Title: Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry
Authors: Joanne N. Davis
Clinton Medbery III
Sanjeev Sharma
David Perry
John Pablo
David J. D’Ambrosio
Heidi McKellar
Frank C. Kimsey
Paul N. Chomiak
Anand Mahadevan
Publication date: 01-03-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Radiation Oncology / Issue 1/2015
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-014-0177-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

Tumor length as a prognostic factor in esophageal cancer management

Hypofractionated intensity-modulated radiation therapy for prostate cancer confined to the pelvis: analysis of efficacy and late toxicity

Hypofractionated radiotherapy with concurrent temozolomide chemotherapy in patients with newly diagnosed RPA class V glioblastoma multiforme: promising early results

Medical radiation dosimetry—theory of charged particle collision energy loss by Brain McParland

[11C]-Choline PET/CT-guided simultaneous integrated boost to dominant intraprostatic lesions using intensity-modulated radiation therapy with helical tomotherapy technique for dose escalation

Is linac-based volumetric modulated arc therapy better than helical tomotherapy in the radiotherapy of nasopharyngeal carcinoma?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer